
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. is showing promising clinical advancements with its lead candidate, PMN310, which has demonstrated favorable safety profiles and pharmacokinetic properties in Phase 1a trials, reinforcing the rationale for its targeted approach to neurodegenerative diseases. Additionally, the dual selectivity profile of PMN267 is expected to enhance its therapeutic potential across a range of TDP-43-driven conditions, including ALS and frontotemporal dementia, thus broadening the company's market prospects. The positive biomarker data obtained from these candidates may justify continued investment as the company approaches final 12-month data releases, suggesting a robust pipeline that addresses significant unmet medical needs in neurodegeneration.
Bears say
ProMIS Neurosciences faces a challenging outlook due to its reliance on research that has not demonstrated consistent positive results in animal models, which may hinder investor confidence in the effectiveness of its therapies. The company is also likely to encounter significant risks related to future partnerships and market competition, potentially affecting its overall market uptake and revenue generation. Additionally, concerns regarding possible near-term dilution risks could further impact its financial stability and attractiveness to investors.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares